Copyright 2009 Medical News Today Latest Prostate / Prostate Cancer News From Medical News Today. http://www.medicalnewstoday.com/sections/prostate/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Mon, 30 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/172439.php http://www.medicalnewstoday.com/articles/172439.php Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate1 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer. Prostate / Prostate Cancer Sun, 29 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/172409.php http://www.medicalnewstoday.com/articles/172409.php UroToday.com - Minimally invasive radical prostatectomy (MIRP) for prostate cancer (CaP) is the most common treatment modality for localized CaP in the United States. The popularity in part is due to marketing and patient driven desire for the procedure. This encompasses both pure laparoscopic radical prostatectomy and robotic-assisted radical prostatectomy. No randomized trial has compared it with open radical retropubic prostatectomy (RP). Prostate / Prostate Cancer Tue, 24 Nov 2009 16:00:00 PST http://www.medicalnewstoday.com/articles/171997.php http://www.medicalnewstoday.com/articles/171997.php ProUroCare Medical Inc. (OTCBB: PUMD) (OTCBB: PUMDU) (OTCBB: PUMDW), a provider of proprietary medical imaging products, announced that a 510(k) application for U.S. market clearance of a prostate mechanical imaging system has been filed with the Food & Drug Administration (FDA). The labeling claim for the device is that it can be used as an aid to visualize and document abnormalities of the prostate detected and/or monitored by digital rectal examination (DRE). Prostate / Prostate Cancer Sat, 21 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171775.php http://www.medicalnewstoday.com/articles/171775.php Dendreon Corporation (Nasdaq: DNDN) announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Prostate / Prostate Cancer Fri, 20 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/171662.php http://www.medicalnewstoday.com/articles/171662.php Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level. Cancer / Oncology Wed, 18 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/171298.php http://www.medicalnewstoday.com/articles/171298.php International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide. Prostate / Prostate Cancer Tue, 17 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171096.php http://www.medicalnewstoday.com/articles/171096.php Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Prostate / Prostate Cancer Mon, 16 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/171054.php http://www.medicalnewstoday.com/articles/171054.php UroToday.com - The present study found that the majority of men with early prostate cancer (PC) included in a protocol-based program for active surveillance (AS) show favorable anxiety and distress scores when compared to reference values and to groups of patients with PC who underwent other treatments. Prostate / Prostate Cancer Mon, 16 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/171061.php http://www.medicalnewstoday.com/articles/171061.php UroToday.com - Accurate prediction of outcome after hormonal treatment for localized prostate cancer is important for patient counselling, follow-up, treatment planning and research protocol design. Few prognostic tools incorporating pre-therapeutic parameters are available to increase disease relapse predictions and survival. Prostate / Prostate Cancer Mon, 16 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/171062.php http://www.medicalnewstoday.com/articles/171062.php UroToday.com - Gonadotrophin-releasing hormone (GnRH) agonists are currently the 'standard of care' for androgen deprivation therapy (ADT) in prostate cancer. Improvements in ADT would have a great value for many patients. The agonists are associated with an initial testosterone surge, which delays castration and may stimulate tumor growth and induce 'clinical flare' in patients with symptomatic advanced disease. Prostate / Prostate Cancer Fri, 13 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/170795.php http://www.medicalnewstoday.com/articles/170795.php Clinicians using RapidArc® radiotherapy technology for fast, precise, non-invasive cancer treatments have found that they are able to substantially reduce scatter dose to surrounding healthy tissues, according to several presentations and posters presented this week at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago. Cancer / Oncology Thu, 12 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/170651.php http://www.medicalnewstoday.com/articles/170651.php Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC. Prostate / Prostate Cancer Wed, 11 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170516.php http://www.medicalnewstoday.com/articles/170516.php New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer. Prostate / Prostate Cancer Tue, 10 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170339.php http://www.medicalnewstoday.com/articles/170339.php In the November 2009 issue of the Journal of Urology, Stanford Medical School researcher Dr. Rodney Anderson and researchers at the National Center for Pelvic Pain Research, in a new study, demonstrated a high correlation between the location of painful trigger points inside the pelvic floor muscles of men with chronic prostatitis and the location in the body where they routinely complain of pain. Urology / Nephrology Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170195.php http://www.medicalnewstoday.com/articles/170195.php Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy. Elevated levels of PSA have traditionally been seen as a potential sign of prostate cancer, leading to the widespread use of PSA testing. Prostate / Prostate Cancer Fri, 06 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/170143.php http://www.medicalnewstoday.com/articles/170143.php Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases. HIV / AIDS Fri, 06 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/170051.php http://www.medicalnewstoday.com/articles/170051.php The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection. It is argued that a rapidly rising PSA may indicate a greater risk of diagnosis of prostate cancer even if PSA levels are low. Prostate / Prostate Cancer Thu, 05 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169983.php http://www.medicalnewstoday.com/articles/169983.php Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival. Their findings were presented this week at the 51st annual meeting of the American Society of Therapeutic Radiology and Oncology in Chicago. Prostate / Prostate Cancer Thu, 05 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169933.php http://www.medicalnewstoday.com/articles/169933.php Men who have used 'Simplicity Health' or 'Fortel' home testing kits for prostate cancer screening during the past 12 months are being urged to contact their GP for advice. This follows recent notification to the Medicines and Healthcare products Regulatory Agency (MHRA) that the two kits from batch number 1012 are faulty and could give a false negative result. The 1000 defective devices shipped to the UK were sold through pharmacies and via the internet. Prostate / Prostate Cancer Thu, 05 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169939.php http://www.medicalnewstoday.com/articles/169939.php A patient's socioeconomic status (income, marital status and race) has absolutely no impact on his outcome following curative radiation therapy for the treatment of prostate cancer, according to a new study from Henry Ford Hospital in Detroit. "This study offers an extremely important message for all patients with prostate cancer who receive radiation therapy," says Benjamin Movsas, M.D. Prostate / Prostate Cancer Thu, 05 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169941.php http://www.medicalnewstoday.com/articles/169941.php Men whose prostate specific antigen (PSA) rise within 18 months of radiotherapy are more likely to develop spread and die of their disease, according to an international study led by Fox Chase Cancer Center radiation oncologist Mark K. Buyyounouski, M.D., M.S. and presented at the annual meeting of the American Society for Radiation Oncology (ASTRO). "PSA is the gold standard for following prostate cancer patients after they receive radiation or surgery. Prostate / Prostate Cancer Thu, 05 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/169846.php http://www.medicalnewstoday.com/articles/169846.php A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed? The answer may lie in the size and shape of the blood vessels that are visible within the cancer, according to research led by investigators at The Ohio State University Comprehensive Cancer Center-Arthur G. Prostate / Prostate Cancer Wed, 04 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169780.php http://www.medicalnewstoday.com/articles/169780.php Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer - an aggressive form of the disease with a poorer prognosis, according to results of a Johns Hopkins collaborative study. In a prospective study of more than 5,000 U.S. men, epidemiologists say they now have evidence that having lower levels of heart-clogging fat may cut a man's risk of this form of cancer by nearly 60 percent. Prostate / Prostate Cancer Wed, 04 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/169774.php http://www.medicalnewstoday.com/articles/169774.php A pair of studies in Cancer Epidemiology, Biomarkers & Prevention, lay to rest the decades-long concern that lower total cholesterol may lead to cancer, and in fact lower cholesterol may reduce the risk of high-grade prostate cancer. Demetrius Albanes, M.D., a senior investigator at the National Cancer Institute, said early studies suggested that low cholesterol could increase the risk of certain types of cancer. Cholesterol Wed, 04 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169822.php http://www.medicalnewstoday.com/articles/169822.php Two new studies from the US published this week negate concerns that have been around since early studies done decades ago suggested that low cholesterol leads to some types of cancer: one in fact affirms that undiagnosed cancer is the likely cause of lower total cholesterol while the other found evidence linking low cholesterol and decreased risk of high-grade prostate cancer among older men. Cholesterol